Abstract PO1-03-09: Transcriptomic profiling of ER-negative and ER-low, HER2-negative breast cancer and its implications on immune regulation
Gaia Griguolo(University of North Carolina at Chapel Hill), Maria Vittoria Dieci(Istituto Oncologico Veneto), Silvia Brich(Fondazione IRCCS Istituto Nazionale dei Tumori), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Federica Miglietta(University of Padua), Andrea Vingiani(Istituti di Ricovero e Cura a Carattere Scientifico), Valentina Guarneri(Istituto Oncologico Veneto), Davide Massa(University of Padua), Matteo Fassan(University of Padua), Francesca Schiavi(Istituto Oncologico Veneto), Giancarlo Pruneri(University of Milan), Lorenzo Nicolè(University of Padua), Claudia Pinato(Istituto Oncologico Veneto), Riccardo Lobefaro(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 0
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|Annals of Oncology|2023|298